Literature DB >> 17418639

Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease.

Nicholas H Carbonetti1.   

Abstract

Bordetella pertussis infection of the airways causes the disease pertussis (or whooping cough). The infection can be fatal in infants, but in older children, adolescents and adults usually results in a chronic cough of varying severity that persists long after clearance of the infection. The cause of the cough is unknown, but is presumably a result of the pathogenic effects of one or more of the various virulence factors produced by this bacterium. Accumulating recent evidence indicates that the majority of the virulence-associated effects of these factors is devoted to suppression and modulation of the host immune response, which can be skewed towards the recently described Th17 profile. Although the interplay between virulence factors and immune mechanisms might have evolved to benefit both partners in the host-pathogen interaction, it could also contribute to the severe disease pathology associated with this infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418639     DOI: 10.1016/j.coph.2006.12.004

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  34 in total

1.  Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines.

Authors:  Neelima Sukumar; Gina Parise Sloan; Matt S Conover; Cheraton F Love; Seema Mattoo; Nancy D Kock; Rajendar Deora
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

2.  Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm.

Authors:  Rui Li; Annabelle Lim; Meng Chee Phoon; Teluguakula Narasaraju; Jowin K W Ng; Wee Peng Poh; Meng Kwoon Sim; Vincent T Chow; Camille Locht; Sylvie Alonso
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 3.  Pertussis pathogenesis--what we know and what we don't know.

Authors:  Erik L Hewlett; Drusilla L Burns; Peggy A Cotter; Eric T Harvill; Tod J Merkel; Conrad P Quinn; E Scott Stibitz
Journal:  J Infect Dis       Date:  2014-04-01       Impact factor: 5.226

4.  Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17.

Authors:  Gizi Wildbaum; Yaniv Zohar; Nathan Karin
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

5.  Intracellular disassembly and activity of pertussis toxin require interaction with ATP.

Authors:  Roger D Plaut; Karen M Scanlon; Michael Taylor; Ken Teter; Nicholas H Carbonetti
Journal:  Pathog Dis       Date:  2016-06-30       Impact factor: 3.166

Review 6.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

Review 7.  Coughing precipitated by Bordetella pertussis infection.

Authors:  Matthew Hewitt; Brendan J Canning
Journal:  Lung       Date:  2010-01       Impact factor: 2.584

8.  Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice.

Authors:  Charlotte Andreasen; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

9.  Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice.

Authors:  Charlotte Andreasen; Daniel A Powell; Nicholas H Carbonetti
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

10.  Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways.

Authors:  Giorgio Fedele; Fabiana Spensieri; Raffaella Palazzo; Maria Nasso; Gordon Yiu Chong Cheung; John Graham Coote; Clara Maria Ausiello
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.